Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme

International Journal of Radiation Oncology, Biology, Physics
Susan ChangMichael D Prados

Abstract

The chemotherapeutic agent temozolomide (TMZ) and the antiangiogenic agent thalidomide have both demonstrated antitumor activity in patients with recurrent malignant glioma. The objectives of this study were to determine if the combined strategy of these oral agents with radiation therapy (RT) is associated with an improved median survival of patients with newly diagnosed glioblastoma multiforme and to evaluate toxicity. Sixty-seven patients were enrolled in this trial. Radiotherapy parameters were a total dose of 60 Gy delivered in 2 Gy fractions over 6 weeks. Temozolomide was administered starting the first day of RT at 150 mg/m(2) daily for 5 days every 4 weeks for the first cycle and escalated to a maximum dose of 200 mg/m(2). Thalidomide was started on Day 7 of RT at 200 mg and escalated by 100-200 mg every 1-2 weeks depending on patient tolerance, to a maximum of 1,200 mg daily. Sixty-one patients have progressed, with a median time to progression of 22 weeks. Fifty-six patients have died, and the median survival was 73 weeks. This strategy of combination TMZ, thalid and RT was relatively well tolerated with favorable survival outcome for patients with GM when compared to patients not treated with adjuvant chemotherapy an...Continue Reading

References

Mar 1, 1991·The Journal of Experimental Medicine·E P SampaioG Kaplan
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roger StuppSerge Leyvraz
Jun 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wen-Jen HwuAlan N Houghton
Jun 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard A FineCraig B Borkowf
Jun 28, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S DansonM R Middleton
Aug 29, 2003·Neurosurgery·Mark R Harrigan
Aug 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wen-Jen HwuAlan N Houghton

❮ Previous
Next ❯

Citations

Jul 29, 2008·Journal of Neuro-oncology·Camilo E FadulJ Marc Pipas
Feb 8, 2008·Current Treatment Options in Oncology·David A ReardonJames J Vredenburgh
May 21, 2011·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Nicholas Butowski
Jun 30, 2009·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Andrew S ChiPatrick Y Wen
Apr 3, 2009·Chemical Reviews·Philip J Tofilon, Kevin Camphausen
Apr 3, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Ilkka LiikanenAkseli Hemminki
Oct 15, 2009·Nature Reviews. Neurology·Andrew D NordenPatrick Y Wen
May 30, 2013·Cancer Biotherapy & Radiopharmaceuticals·Julia Alejandra PezukLuiz Gonzaga Tone
Sep 1, 2007·Anti-cancer Drugs·Riccardo SoffiettiElisa Trevisan
Jan 7, 2009·Journal of Pediatric Hematology/oncology·David S Dickens, Paul T Jubinsky
Mar 20, 2013·BioMed Research International·Michio YoshimuraMasahiro Hiraoka
Dec 23, 2011·Radiation Oncology·Maximilian NiyaziClaus Belka
Sep 11, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dan G DudaChristopher G Willett
Dec 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael D PradosDaphne A Haas-Kogan
Oct 5, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mei-Yin C PolleyMichael Prados
Jan 1, 2009·OncoTargets and Therapy·Rimas V LukasM Kelly Nicholas
May 24, 2011·Clinical Medicine Insights. Oncology·Marc C Chamberlain
Feb 11, 2014·Current Oncology Reports·Mohamed Ali Hamza, Mark Gilbert
May 4, 2005·Current Neurology and Neuroscience Reports·Roger StuppMonika E Hegi
Sep 16, 2014·Seminars in Radiation Oncology·Jennifer L Clarke
Nov 21, 2007·Expert Review of Anticancer Therapy·Andrew ChiPatrick Y Wen
Jan 10, 2008·Expert Review of Anticancer Therapy·Rimas V LukasM Kelly Nicholas
Jan 10, 2008·Expert Review of Anticancer Therapy·M Kelly Nicholas
Nov 9, 2005·Expert Review of Neurotherapeutics·M Kelly NicholasSamir Bangalore
Oct 22, 2008·Expert Review of Neurotherapeutics·Sajani S Lakka, Jasti S Rao
Aug 24, 2006·Expert Review of Anticancer Therapy·Nicole Mutter, Roger Stupp
Jul 12, 2005·Expert Opinion on Investigational Drugs·Michele ReniAlba A Brandes
Nov 29, 2007·Expert Opinion on Investigational Drugs·Elizabeth R GerstnerTracy T Batchelor
Jun 2, 2012·Expert Opinion on Drug Discovery·David A ReardonWolfgang Wick
Nov 27, 2007·Expert Opinion on Pharmacotherapy·Tomokazu AokiMasao Matsutani
Feb 13, 2009·Current Medical Research and Opinion·Renato V La Rocca, H Maximilian Mehdorn
Sep 24, 2011·Seminars in Radiation Oncology·Ik Jae Lee, Jinsil Seong
May 7, 2011·Cancer Treatment Reviews·Renaud MazeronEric Deutsch
Sep 8, 2010·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Yu-Hui ZhangJian-Min Liu
Jun 16, 2010·Pharmacology & Therapeutics·Leopold ArkoJohn K Park
Feb 9, 2010·International Journal of Radiation Oncology, Biology, Physics·Jan DrappatzPatrick Y Wen
Aug 22, 2009·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·R MazeronE Deutsch
Nov 15, 2008·Lancet Neurology·Andrew D NordenPatrick Y Wen
Sep 17, 2008·International Journal of Radiation Oncology, Biology, Physics·Ashwatha NarayanaMichael L Gruber
Jun 3, 2008·International Journal of Radiation Oncology, Biology, Physics·Jan DrappatzPatrick Y Wen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.